| Abstrakt: |
Researchers at Virginia Mason Medical Center have published new data on Bing-Neel Syndrome (BNS), a rare manifestation of Waldenstrom macroglobulinemia (WM) that involves the infiltration of malignant lymphoplasmacytic cells into the central nervous system (CNS). The researchers presented a case study of a 70-year-old male with BNS who had previously been treated for WM and experienced symptoms such as weakness, headache, and ataxia. The patient was successfully treated with the Bruton tyrosine kinase inhibitor (BTKI) ibrutinib, resulting in significant clinical and radiologic responses. The study highlights the importance of molecular testing and the potential of BTK inhibitors in treating BNS. [Extracted from the article] |
